essential drugs to the consumers. Ministry of Health being a consumer Ministry may have to consider such variables which affect availability of drugs for its Health Programmes.

(d) There is no such proposal.

Likely incentives from change of category of bulk drugs

2736. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to the answer to Unstarred Question 156 given in the Rajya Sabha on the 27th July, 1988 and state:

(a) what is the locus standi of the Ministry of Health and Family Welfare in deciding the technology contents of drugs;

(b) whether it is a fact that all bulk drugs, independent of their category are allowed a 14 per cent return on net worth;

(c) what additional incentives the change of category of bulk drugs would bring to the producers;

(d) whether it is a fact that the said incentives would mean additional burden on the poor T.B. patients;

(e) whether it is a fact that the said decision has been taken without any justification based on the inducements, hospitality and other offers to the bureaucrats from the industrialists;

(f) what steps have been taken to fix the responsibility; and

(g) whether the decision has been taken with the approval of Government?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Ministry of Health and Family Welfare may recommend re-categorisation to the Department of Chemicals to ensure availability of essential drugs required under the National Health Programmes. Department of Chemicals, however,, is the concerned body for final listing of drugs.

(b) 14 percent post-tax return on net worth or 22 per cent return on capital employed on long term marginal costing with 12 percent internal rate of return in the case of new plants have been norms for option for all bulk drugs under Category I and II.

(c) Recategorisation would give incentives to bulk manufacture for captive consumption.

(d) and (g) Any undue burden to the patients in terms of unjustified price rise would be monitored by Department of Chemicals and in such cases rectifying measure would be taken. Decisions for recategorisation are based on sound scientific rationale. Any such decision considered rationals will have the approval of the Government.

(e) This is not correct.

(f) In view of (e) above, does not arise.

Usage and sale of eye drops

2737. SHRI JAGESH DESAI:
SHRI JASWANT SINGH:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to answer to Unstarred Question 157 given in the Rajya Sabha on the 27th July, 1988 and state:

(a) whether in terms of usuage and sales eye drops of Gentamycin, Framycin, Dexamethasone and Betamethasone are used more extensively, as compared to the eye drops of Tetracycline and Hydrochortisone;

(b) whether it is a fact that due to irritation effelts, Hydrocortisone drops as a single ingredient, are rarely used;